US FDA seeks comments on draft guidance on user fee waivers, reductions and refunds
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has published for stakeholder comment draft guidance on how sponsors of drugs and biologicals can request user fee waivers, refunds or reductions1,2.